Priority Date: 7/9/2021

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	CAAMTECH Inc	Confirmation No.: 8493
Serial No.:	18/260,711	Group No.:
Filing or 371(c) Date:	July 7, 2023	Examiner:

Entitled: PROTECTED ALKYL TRYPTAMINES AND THEIR THERAPEUTIC USES

THIRD-PARTY PRE-ISSUANCE SUBMISSION

Examiner:

The following documents, which are also identified in the Form PTO/SB/429 filed herewith, are submitted for your consideration as being of potential relevance to the examination of the present application.

1. U.S. Pat. App. Pub. No. US/2016/0353739 "Use of aryl carbamates in agriculture and other plant-related areas" (Published December 8, 2016)
2. Int'l Pat. App. Pub. No. WO/2003/035,061 "Use of indole and indoline derivatives in the treatment of obesity or for the reduction of food intake" (Published May 1, 2003)
3. U.S. Pat. App. Pub. No. US/2018/0021326 "Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin" (Published 25 January 2018)

Attached hereto is a claim chart providing a concise description of the relevance of each reference in the document list to the elements of the presently pending claims.

U.S.S.N. 18/260,711 Pending Claims	References
55. A tryptamine compound selected from the group consisting of: a tryptamine compound of formula (Ia):  wherein R1a is selected from a straight chain or branched C1-C6 alkyl or a straight chain or branched C2-C6 alkenyl; R2a is —C(O)OR10a, and wherein R10a is selected from optionally substituted C1-C6 alkyl that is branched or unbranched, and optionally substituted aryl; R3a and R4a are independently chosen from hydrogen, hydroxyl, —OR9a, —OC(O)R5a, —OC(O)OR5a, or —OSO2R5a, provided that at least one of R3a or R4a is hydroxyl, —	*From the application of interest 18/260,711, Claim 1:* *A tryptamine compound selected from the group consisting of:* *a* ***tryptamine compound of formula (Ia)****:*  *wherein* ***R1a is selected from a straight chain or branched C1****-C6* ***alkyl*** *or a straight chain or branched C2-C6 alkenyl;* ***R2a is —C(O)OR10a, and wherein R10a is selected from optionally substituted C1****-C6* ***alkyl*** *that is branched or unbranched, and optionally substituted aryl;* ***R3a and R4a are independently chosen from hydrogen****, hydroxyl, —OR9a, —OC(O)R5a, —OC(O)OR5a, or —OSO2R5a, provided that at least one of R3a or R4a is hydroxyl, —OR9a, —OC(O)R5a, —OC(O)OR5a, or —OSO2R5a;* *R5a is a straight chain or branched C1-C6 alkyl or a substituted or unsubstituted aryl;* *R9a is selected from a protecting group, a straight chain or branched C1-C6 alkyl, or a substituted or unsubstituted aryl; and* ***R6a, R7a, R8a, and R11a are each independently hydrogen*** *or a straight chain or branched C1-C6 alkyl; and* ***R12a is selected from hydrogen****, a straight chain or branched C1-C6 alkyl or a straight chain or branched C2-C6 alkenyl;* *or a pharmaceutically acceptable acid-addition salt thereof;* 1. U.S. Pat. App. Pub. No. US/2016/0353739 “Use of aryl carbamates in agriculture and other plant-related areas” (Published December 8, 2016)

OR9a, —OC(O)R5a, —OC(O)OR5a, or —OSO2R5a; R5a is a straight chain or branched C1-C6 alkyl or a substituted or unsubstituted aryl; R9a is selected from a protecting group, a straight chain or branched C1-C6 alkyl, or a substituted or unsubstituted aryl; and R6a, R7a, R8a, and R11a are each independently hydrogen or a straight chain or branched C1-C6 alkyl; and R12a is selected from hydrogen, a straight chain or branched C1-C6 alkyl or a straight chain or branched C2-C6 alkenyl; or a pharmaceutically acceptable acid-addition salt thereof; with the proviso that when R3a is —OR9a and R9a is methyl, then R2a is neither ethoxycarbonyl or phenoxycarbonyl; with the proviso that when R3a, R6a, R8a, and R11a are all hydrogen, R1a is methyl, R2a is —C(O)OR10a, R12a is methyl, and R4a is methoxy, then R10a is not ethyl; and with the proviso that when R3a, R6a, R8a, and R11a are all hydrogen, R1a is methyl, R2a is —C(O)OR10a, R12a is	From **Claim 1:** A method of preventing, removing or inhibiting microbial biofilm formation or microbial infection in a plant or plant part thereof, comprising applying to said plant or plant part a treatment effective amount of a compound of **Formula (I)**:  wherein: **R1 is an** aryl, an amine-substituted aryl, or a **heteroaryl having at least one nitrogen atom; n=0 to 10**, saturated or unsaturated; **each occurrence of Rx and Ry** is present or absent (depending upon chain saturation), and **is each independently H** or alkyl; **R2 is selected from the group consisting of**: H, **alkyl**, alkenyl and alkynyl; and **R3 is alkyl**, substituted cycloalkyl or unsubstituted cycloalkyl, or an agriculturally acceptable salt thereof. From **Description**: **"Heteroaryl" means a cyclic, aromatic hydrocarbon in which one or more carbon atoms have been replaced with heteroatoms (e.g., N, O or S). If the heteroaryl group contains more than one heteroatom, the heteroatoms may be the same or different. Examples of heteroaryl groups include** pyridyl, pyrimidinyl, imidazolyl, thienyl, furyl, pyrazinyl, pyrrolyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, **indolyl**, isoindolyl, indolizinyl, triazolyl, pyridazinyl, indazolyl, purinyl, quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, isothiazolyl, and benzo[b]thienyl. Preferred heteroaryl groups are five and six membered rings and contain from one to three heteroatoms independently selected from the group consisting of: O, N, and S. **The heteroaryl group, including each heteroatom, can be unsubstituted or substituted with from 1 to 4 suitable substituents, as chemically feasible.** *From the application of interest 18/260,711, Claim 1:* *a tryptamine compound of formula (Ib):*  *wherein:*

hydrogen, and R4a is methoxy, then R10a is not methyl; a tryptamine compound of formula (Ib:  (Ib) wherein: R1b is selected from hydrogen, straight chain or branched C1-C6 alkyl or a straight chain or branched C2-C6 alkenyl; R2b is selected from a protecting group, hydrogen, straight chain or branched C1-C6 alkyl or a straight chain or branched C2-C6 alkenyl; R3b and R4b are independently chosen from hydrogen, hydroxyl, —OR9b, —OC(O)R5b, —OC(O)OR5b, or —OSO2R5b, provided that at least one of R3b or R4b is hydroxyl, —OR9b, —OC(O)R5b, —OC(O)OR5b, or —OSO2R5b; R5b is a straight chain or branched C1-C6 alkyl or a substituted or unsubstituted aryl; R9b is selected from a protecting group, a straight chain or branched C1-C6 alkyl, or a substituted or unsubstituted aryl; R11b is hydrogen;	***R1b is selected from hydrogen, straight chain or branched C1-C6 alkyl*** *or a straight chain or branched C2-C6 alkenyl;* ***R2b is selected from*** *a protecting group,* ***hydrogen, straight chain or branched C1-C6 alkyl*** *or a straight chain or branched C2-C6 alkenyl;* ***R3b and R4b are independently chosen from hydrogen, hydroxyl, —OR9b****, —OC(O)R5b, —OC(O)OR5b, or —OSO2R5b, provided that at least one of R3b or R4b is hydroxyl, —OR9b, —OC(O)R5b, —OC(O)OR5b, or —OSO2R5b;* *R5b is a straight chain or branched C1-C6 alkyl or a substituted or unsubstituted aryl;* *R9b is selected from a protecting group, a straight chain or branched C1-C6 alkyl, or a substituted or unsubstituted aryl;* ***R11b is hydrogen****;* ***R12b is a protecting group****; and* ***R6b, R7b, and R8b are each independently hydrogen or a straight chain or branched C1-C6 alkyl****;* *or a pharmaceutically acceptable acid-addition salt thereof;* *with the proviso that when R1b is hydrogen, R2b is methyl, R6b, R7b, and R8b are all hydrogen, and R12b is tert-butyloxycarbonyl (BOC) or methoxycarbonyl, then R3b is not hydrogen or methoxy; and* *with the proviso that when R1b and R2b are methyl, R6b, R7b, and R8b are all hydrogen, and R12b is ethoxycarbonyl, then R3b and R4b are not both methyl* 2. Int'l Pat. App. Pub. No. WO/2003/035,061 "Use of indole and indoline derivatives in the treatment of obesity or for the reduction of food intake" (Published May 1, 2003) From **Claim 1**: **Use of a compound having a structure in accordance with Formula** I, **II** or III:  **wherein n is 1** or 2... **R1 and R2 independently represent hydrogen, C1-C6 alkyl** or aryl, C1-C6 alkyl, or together represent the atoms necessary to complete a heterocycloalkyl group comprising the nitrogen atom to which R1 and R2 are attached;

R12b is a protecting group; and R6b, R7b, and R8b are each independently hydrogen or a straight chain or branched C1-C6 alkyl; or a pharmaceutically acceptable acid-addition salt thereof; with the proviso that when R1b is hydrogen, R2b is methyl, R6b, R7b, and R8b are all hydrogen, and R12b is tert-butyloxycarbonyl (BOC) or methoxycarbonyl, then R3b is not hydrogen or methoxy; and with the proviso that when R1b and R2b are methyl, R6b, R7b, and R8b are all hydrogen, and R12b is ethoxycarbonyl, then R3b and R4b are not both methyl; and a tryptamine compound of formula (I):  (I) wherein R1 is selected from hydrogen, straight chain or branched C1-C6 alkyl or a straight chain or branched C2-C6 alkenyl; R2 is selected from a protecting group, hydrogen, straight chain or branched C1-C6 alkyl or a straight	**R3 represents hydrogen**, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, C1-C6alkyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, C_ alkylcarbonyl, or C1-C6 alkoxycarbonyl; **R4 represents arylsulphonyl**, heteroarylsulphonyl, Cj-g alkylsulphonyl, di C1-C6 alkylaminosulphonyl, arylcarbonyl, C-C6 alkylcarbonyl, heteroarylcarbonyl or C1-C6 alkoxycarbonyl; **each R5 independently represents hydrogen, hydroxy**, **C1-C6 alkoxy**, aryl C1-C6 alkoxy, nitrile or halogen;... **and A-B represents C=C** or CH-CH, in the manufacture of a medicament for the treatment and/or prevention of obesity or for the reduction of food intake. *From the application of interest 18/260,711, Claim 1:* *a tryptamine compound of formula (I):*  (I) *wherein* ***R1 is selected from hydrogen, straight chain or branched C1-C6 alkyl** or a straight chain or branched C2-C6 alkenyl;* ***R2 is selected from** a protecting group, **hydrogen, straight chain or branched C1-C6 alkyl** or a straight chain or branched C2-C6 alkenyl;* ***R3 and R4 are independently chosen from hydrogen, hydroxyl, —OR9,** —OC(O)R5, —OC(O)OR5, or —OSO2R5;* *R5 is a straight chain or branched C1-C6 alkyl or a substituted or unsubstituted aryl;* ***R9 is selected from** a protecting group, **a straight chain or branched C1-C6 alkyl, or a substituted or unsubstituted aryl**;* ***R6, R7, R8, and R11 are each independently hydrogen** or a straight chain or branched C1-C6 alkyl; and* ***R12 is selected from a protecting grou**p, hydrogen, a straight chain or branched C1-C6 alkyl or a straight chain or branched C2-C6 alkenyl, wherein at least one of R2 or R12 is a protecting group;* *or a pharmaceutically acceptable acid-addition salt thereof;* ***wherein the purity of the tryptamine compound of formula (I) is greater than 98%.*** 2. Int'l Pat. App. Pub. No. WO/2003/035,061 "Use of indole and indoline derivatives in the treatment of obesity or for the reduction of food intake" (Published May 1, 2003) From **Claim 1**: **Use of a compound having a structure in accordance with Formula** I, **II** or III:

chain or branched C2-C6 alkenyl; R3 and R4 are independently chosen from hydrogen, hydroxyl, —OR9, —OC(O)R5, —OC(O)OR5, or —OSO2R5; R5 is a straight chain or branched C1-C6 alkyl or a substituted or unsubstituted aryl; R9 is selected from a protecting group, a straight chain or branched C1-C6 alkyl, or a substituted or unsubstituted aryl; R6, R7, R8, and R11 are each independently hydrogen or a straight chain or branched C1-C6 alkyl; and R12 is selected from a protecting group, hydrogen, a straight chain or branched C1-C6 alkyl or a straight chain or branched C2-C6 alkenyl, wherein at least one of R2 or R12 is a protecting group; or a pharmaceutically acceptable acid-addition salt thereof; wherein the purity of the tryptamine compound of formula (I) is greater than 98%.	 **wherein n is 1** or 2... **R1 and R2 independently represent hydrogen, C1-C6 alkyl** or aryl, C1-C6 alkyl, or together represent the atoms necessary to complete a heterocycloalkyl group comprising the nitrogen atom to which R1 and R2 are attached; **R3 represents hydrogen**, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, C1-C6alkyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, C_ alkylcarbonyl, or C1-C6 alkoxycarbonyl; **R4 represents arylsulphonyl**, heteroarylsulphonyl, Cj-g alkylsulphonyl, di C1-C6 alkylaminosulphonyl, arylcarbonyl, C-C6 alkylcarbonyl, heteroarylcarbonyl or C1-C6 alkoxycarbonyl; **each R5 independently represents hydrogen, hydroxy**, **C1-C6 alkoxy**, aryl C1-C6 alkoxy, nitrile or halogen;... **and A-B represents C=C** or CH-CH, in the manufacture of a medicament for the treatment and/or prevention of obesity or for the reduction of food intake. From **Description**: **Compound: The test compound, N,N-Dimethyl 2-[1 -(benzenesulphonyl)-5-methoxy- 1 H-indol-3-yl]ethylamine**. **The purity of the test compounds is of analytical grade.** From **Description**: **Consequently, the present invention provides a method for the treatment or prophylaxis of obesity or for the reduction of food intake in mammals, including humans**. **The method comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound** of formula I, II or III
56. The compound of claim 55, wherein the tryptamine compound is a compound of formula (Ia).	*From the application of interest 18/260,711, Claim 1:* *A tryptamine compound selected from the group consisting of:* *a **tryptamine compound of formula (Ia)**:wherein*

	R1a is selected from a straight chain or branched C1-C6 alkyl *or a straight chain or branched C2-C6 alkenyl;* ***R2a is —C(O)OR10a, and wherein R10a is selected from optionally substituted C1-C6 alkyl*** *that is branched or unbranched, and optionally substituted aryl;* ***R3a and R4a are independently chosen from hydrogen****, hydroxyl, —OR9a, —OC(O)R5a, —OC(O)OR5a, or —OSO2R5a, provided that at least one of R3a or R4a is hydroxyl, —OR9a, —OC(O)R5a, —OC(O)OR5a, or —OSO2R5a;* *R5a is a straight chain or branched C1-C6 alkyl or a substituted or unsubstituted aryl;* *R9a is selected from a protecting group, a straight chain or branched C1-C6 alkyl, or a substituted or unsubstituted aryl; and* ***R6a, R7a, R8a, and R11a are each independently hydrogen*** *or a straight chain or branched C1-C6 alkyl; and* ***R12a is selected from hydrogen****, a straight chain or branched C1-C6 alkyl or a straight chain or branched C2-C6 alkenyl;* *or a pharmaceutically acceptable acid-addition salt thereof;* 1. U.S. Pat. App. Pub. No. US/2016/0353739 "Use of aryl carbamates in agriculture and other plant-related areas" (Published December 8, 2016) From **Claim 1:** A method of preventing, removing or inhibiting microbial biofilm formation or microbial infection in a plant or plant part thereof, comprising applying to said plant or plant part a treatment effective amount of a compound of **Formula (I)**:  wherein: **R1 is an** aryl, an amine-substituted aryl, or a **heteroaryl having at least one nitrogen atom; n=0 to 10**, saturated or unsaturated; **each occurrence of Rx and Ry** is present or absent (depending upon chain saturation), and **is each independently H** or alkyl; **R2 is selected from the group consisting of**: H, **alkyl**, alkenyl and alkynyl; and **R3 is alkyl**, substituted cycloalkyl or unsubstituted cycloalkyl, or an agriculturally acceptable salt thereof. From **Description**: **"Heteroaryl" means a cyclic, aromatic hydrocarbon in which one or more carbon atoms have been replaced with**

	heteroatoms (e.g., N, O or S). If the heteroaryl group contains more than one heteroatom, the heteroatoms may be the same or different. Examples of heteroaryl groups include pyridyl, pyrimidinyl, imidazolyl, thienyl, furyl, pyrazinyl, pyrrolyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, **indolyl**, isoindolyl, indolizinyl, triazolyl, pyridazinyl, indazolyl, purinyl, quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, isothiazolyl, and benzo[b]thienyl. Preferred heteroaryl groups are five and six membered rings and contain from one to three heteroatoms independently selected from the group consisting of: O, N, and S. **The heteroaryl group, including each heteroatom, can be unsubstituted or substituted with from 1 to 4 suitable substituents, as chemically feasible.**
57. The compound of claim 56, wherein R2a and R9a are independently selected from a tert-butyloxycarbonyl (BOC) group, a fluorenylmethyloxycarbonyl (FMOC) group, a benzyloxycarbonyl (Cbz or Z) group, an allyloxycarbonyl (Alloc) group, a 2,2,2-Trichloroethoxycarbonyl (Troc) group, or a 2-(Trimethylsilyl)ethoxycarbonyl (Teoc) group.	*From the application of interest 18/260,711, Claim 1:* *A tryptamine compound selected from the group consisting of:* *a **tryptamine compound of formula (Ia)**:*  (Ia) *wherein* ***R1a is selected from a straight chain or branched C1**-C6 **alkyl** or a straight chain or branched C2-C6 alkenyl;* ***R2a is —C(O)OR10a, and wherein R10a is selected from optionally substituted C1**-C6 **alkyl** that is branched or unbranched, and optionally substituted aryl;* ***R3a and R4a are independently chosen from hydrogen**, hydroxyl, —**OR9a**, —OC(O)R5a, —OC(O)OR5a, or —OSO2R5a, provided that at least one of R3a or R4a is hydroxyl, —OR9a, —OC(O)R5a, —OC(O)OR5a, or —OSO2R5a;* *R5a is a straight chain or branched C1-C6 alkyl or a substituted or unsubstituted aryl;* *R9a is selected from a protecting group, a straight chain or branched C1-C6 alkyl, or a substituted or unsubstituted aryl; and* ***R6a, R7a, R8a, and R11a are each independently hydrogen** or a straight chain or branched C1-C6 alkyl; and* ***R12a is selected from hydrogen**, a straight chain or branched C1-C6 alkyl or a straight chain or branched C2-C6 alkenyl;* *or a pharmaceutically acceptable acid-addition salt thereof;* 1. U.S. Pat. App. Pub. No. US/2016/0353739 “Use of aryl carbamates in agriculture and other plant-related areas” (Published December 8, 2016)

	From **Claim 1:** A method of preventing, removing or inhibiting microbial biofilm formation or microbial infection in a plant or plant part thereof, comprising applying to said plant or plant part a treatment effective amount of a compound of **Formula (I)**:  wherein: **R1 is an** aryl, an amine-substituted aryl, or a **heteroaryl having at least one nitrogen atom; n=0 to 10**, saturated or unsaturated; **each occurrence of Rx and Ry** is present or absent (depending upon chain saturation), and **is each independently H** or alkyl; **R2 is selected from the group consisting of**: H, **alkyl**, alkenyl and alkynyl; and **R3 is alkyl**, substituted cycloalkyl or unsubstituted cycloalkyl, or an agriculturally acceptable salt thereof. From **Description**: **"Heteroaryl" means a cyclic, aromatic hydrocarbon in which one or more carbon atoms have been replaced with heteroatoms (e.g., N, O or S). If the heteroaryl group contains more than one heteroatom, the heteroatoms may be the same or different. Examples of heteroaryl groups include** pyridyl, pyrimidinyl, imidazolyl, thienyl, furyl, pyrazinyl, pyrrolyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, **indolyl**, isoindolyl, indolizinyl, triazolyl, pyridazinyl, indazolyl, purinyl, quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, isothiazolyl, and benzo[b]thienyl. Preferred heteroaryl groups are five and six membered rings and contain from one to three heteroatoms independently selected from the group consisting of: O, N, and S. **The heteroaryl group, including each heteroatom, can be unsubstituted or substituted with from 1 to 4 suitable substituents, as chemically feasible.**
58. The compound of claim 56, wherein at least one of R3a, R4a, R6a, R7a, and R8a is not hydrogen.	*From the application of interest 18/260,711, Claim 1:* *A tryptamine compound selected from the group consisting of:* *a **tryptamine compound of formula (Ia)**:*  *wherein*

	R1a is selected from a straight chain or branched C1-C6 alkyl *or a straight chain or branched C2-C6 alkenyl;* ***R2a is —C(O)OR10a, and wherein R10a is selected from optionally substituted C1-C6 alkyl*** *that is branched or unbranched, and optionally substituted aryl;* ***R3a and R4a are independently chosen from hydrogen****, hydroxyl, —OR9a, —OC(O)R5a, —OC(O)OR5a, or —OSO2R5a, provided that at least one of R3a or R4a is hydroxyl, —OR9a, —OC(O)R5a, —OC(O)OR5a, or —OSO2R5a;* *R5a is a straight chain or branched C1-C6 alkyl or a substituted or unsubstituted aryl;* *R9a is selected from a protecting group, a straight chain or branched C1-C6 alkyl, or a substituted or unsubstituted aryl; and* ***R6a, R7a, R8a, and R11a are each independently hydrogen*** *or a straight chain or branched C1-C6 alkyl; and* ***R12a is selected from hydrogen****, a straight chain or branched C1-C6 alkyl or a straight chain or branched C2-C6 alkenyl;* *or a pharmaceutically acceptable acid-addition salt thereof;* 1. U.S. Pat. App. Pub. No. US/2016/0353739 "Use of aryl carbamates in agriculture and other plant-related areas" (Published December 8, 2016) From **Claim 1:** A method of preventing, removing or inhibiting microbial biofilm formation or microbial infection in a plant or plant part thereof, comprising applying to said plant or plant part a treatment effective amount of a compound of **Formula (I)**:  wherein: **R1 is an** aryl, an amine-substituted aryl, or a **heteroaryl having at least one nitrogen atom; n=0 to 10**, saturated or unsaturated; **each occurrence of Rx and Ry** is present or absent (depending upon chain saturation), and **is each independently H** or alkyl; **R2 is selected from the group consisting of**: H, **alkyl**, alkenyl and alkynyl; and **R3 is alkyl**, substituted cycloalkyl or unsubstituted cycloalkyl, or an agriculturally acceptable salt thereof. From **Description**: **"Heteroaryl" means a cyclic, aromatic hydrocarbon in which one or more carbon atoms have been replaced with heteroatoms (e.g., N, O or S). If the heteroaryl group contains more**

	than one heteroatom, the heteroatoms may be the same or different. Examples of heteroaryl groups include pyridyl, pyrimidinyl, imidazolyl, thienyl, furyl, pyrazinyl, pyrrolyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, **indolyl**, isoindolyl, indolizinyl, triazolyl, pyridazinyl, indazolyl, purinyl, quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, isothiazolyl, and benzo[b]thienyl. Preferred heteroaryl groups are five and six membered rings and contain from one to three heteroatoms independently selected from the group consisting of: O, N, and S. **The heteroaryl group, including each heteroatom, can be unsubstituted or substituted with from 1 to 4 suitable substituents, as chemically feasible.**
59. The compound of claim 56, with the proviso that R9a is not methyl when R4a is —OR9a.	*From the application of interest 18/260,711, Claim 1:* *A tryptamine compound selected from the group consisting of:* *a* ***tryptamine compound of formula (Ia)****:*  (Ia) *wherein* ***R1a is selected from a straight chain or branched C1****-C6* ***alkyl*** *or a straight chain or branched C2-C6 alkenyl;* ***R2a is —C(O)OR10a, and wherein R10a is selected from optionally substituted C1****-C6* ***alkyl*** *that is branched or unbranched, and optionally substituted aryl;* ***R3a and R4a are independently chosen from hydrogen****, hydroxyl, —OR9a, —OC(O)R5a, —OC(O)OR5a, or —OSO2R5a, provided that at least one of R3a or R4a is hydroxyl, —OR9a, —OC(O)R5a, —OC(O)OR5a, or —OSO2R5a;* *R5a is a straight chain or branched C1-C6 alkyl or a substituted or unsubstituted aryl;* *R9a is selected from a protecting group, a straight chain or branched C1-C6 alkyl, or a substituted or unsubstituted aryl; and* ***R6a, R7a, R8a, and R11a are each independently hydrogen*** *or a straight chain or branched C1-C6 alkyl; and* ***R12a is selected from hydrogen****, a straight chain or branched C1-C6 alkyl or a straight chain or branched C2-C6 alkenyl;* *or a pharmaceutically acceptable acid-addition salt thereof;* 1. U.S. Pat. App. Pub. No. US/2016/0353739 “Use of aryl carbamates in agriculture and other plant-related areas” (Published December 8, 2016) From **Claim 1:** A method of preventing, removing or inhibiting microbial biofilm formation or microbial infection in a plant or plant part thereof,

	comprising applying to said plant or plant part a treatment effective amount of a compound of **Formula (I)**:  wherein: **R1 is an** aryl, an amine-substituted aryl, or a **heteroaryl having at least one nitrogen atom; n=0 to 10**, saturated or unsaturated; **each occurrence of Rx and Ry** is present or absent (depending upon chain saturation), and **is each independently H** or alkyl; **R2 is selected from the group consisting of**: H, **alkyl**, alkenyl and alkynyl; and **R3 is alkyl**, substituted cycloalkyl or unsubstituted cycloalkyl, or an agriculturally acceptable salt thereof. From **Description**: **"Heteroaryl" means a cyclic, aromatic hydrocarbon in which one or more carbon atoms have been replaced with heteroatoms (e.g., N, O or S). If the heteroaryl group contains more than one heteroatom, the heteroatoms may be the same or different. Examples of heteroaryl groups include** pyridyl, pyrimidinyl, imidazolyl, thienyl, furyl, pyrazinyl, pyrrolyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, **indolyl**, isoindolyl, indolizinyl, triazolyl, pyridazinyl, indazolyl, purinyl, quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, isothiazolyl, and benzo[b]thienyl. Preferred heteroaryl groups are five and six membered rings and contain from one to three heteroatoms independently selected from the group consisting of: O, N, and S. **The heteroaryl group, including each heteroatom, can be unsubstituted or substituted with from 1 to 4 suitable substituents, as chemically feasible.**
60. The compound of claim 55, wherein the tryptamine compound is a compound of formula (Ib).	*From the application of interest 18/260,711, Claim 1:* *a tryptamine compound of formula (Ib):*  *wherein:* ***R1b is selected from hydrogen, straight chain or branched C1-C6 alkyl*** *or a straight chain or branched C2-C6 alkenyl;* ***R2b is selected from*** *a*

	protecting group, ***hydrogen, straight chain or branched C1-C6 alkyl*** *or a straight chain or branched C2-C6 alkenyl;* *R3b and R4b are independently chosen from* ***hydrogen, hydroxyl, —OR9b****, —OC(O)R5b, —OC(O)OR5b, or —OSO2R5b, provided that at least one of R3b or R4b is hydroxyl, —OR9b, —OC(O)R5b, —OC(O)OR5b, or —OSO2R5b;* *R5b is a straight chain or branched C1-C6 alkyl or a substituted or unsubstituted aryl;* *R9b is selected from a protecting group, a straight chain or branched C1-C6 alkyl, or a substituted or unsubstituted aryl;* ***R11b is hydrogen****;* ***R12b is a protecting group****; and* ***R6b, R7b, and R8b are each independently hydrogen or a straight chain or branched C1-C6 alkyl****;* *or a pharmaceutically acceptable acid-addition salt thereof;* *with the proviso that when R1b is hydrogen, R2b is methyl, R6b, R7b, and R8b are all hydrogen, and R12b is tert-butyloxycarbonyl (BOC) or methoxycarbonyl, then R3b is not hydrogen or methoxy; and* *with the proviso that when R1b and R2b are methyl, R6b, R7b, and R8b are all hydrogen, and R12b is ethoxycarbonyl, then R3b and R4b are not both methyl* 2. Int'l Pat. App. Pub. No. WO/2003/035,061 "Use of indole and indoline derivatives in the treatment of obesity or for the reduction of food intake" (Published May 1, 2003) From **Claim 1**: **Use of a compound having a structure in accordance with Formula** I, **II** or III:  **wherein n is 1** or 2... **R1 and R2 independently represent hydrogen, C1-C6 alkyl** or aryl, C1-C6 alkyl, or together represent the atoms necessary to complete a heterocycloalkyl group comprising the nitrogen atom to which R1 and R2 are attached; **R3 represents hydrogen**, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, C1-C6alkyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, C_ alkylcarbonyl, or C1-C6 alkoxycarbonyl; **R4 represents** arylsulphonyl, heteroarylsulphonyl, Cj-g alkylsulphonyl, di C1-C6 alkylaminosulphonyl, arylcarbonyl, C-C6 alkylcarbonyl, heteroarylcarbonyl or **C1-C6 alkoxycarbony**l; **each R5 independently represents hydrogen, hydroxy**, **C1-C6 alkoxy**, aryl C1-C6 alkoxy, nitrile or halogen;... **and A-B represents**

	C=C or CH-CH, in the manufacture of a medicament for the treatment and/or prevention of obesity or for the reduction of food intake.
61. The compound of claim 60, wherein R12b is selected from a tert-butyloxycarbonyl (BOC) group, a fluorenylmethyloxycarbonyl (FMOC) group, a benzyloxycarbonyl (Cbz or Z) group, a p-methoxybenzyl carbonyl (Moz or MeOZ) group, an allyloxycarbonyl (Alloc) group, a 2,2,2-Trichloroethoxycarbonyl (Troc) group, or a 2-(Trimethylsilyl)ethoxycarbonyl (Teoc) group.	*From the application of interest 18/260,711, Claim 1:* *a tryptamine compound of formula (Ib):*  *wherein:* ***R1b is selected from hydrogen, straight chain or branched C1-C6 alkyl*** *or a straight chain or branched C2-C6 alkenyl;* ***R2b is selected from*** *a protecting group,* ***hydrogen, straight chain or branched C1-C6 alkyl*** *or a straight chain or branched C2-C6 alkenyl;* *R3b and R4b are independently chosen from* ***hydrogen, hydroxyl, —OR9b****, —OC(O)R5b, —OC(O)OR5b, or —OSO2R5b, provided that at least one of R3b or R4b is hydroxyl, —OR9b, —OC(O)R5b, —OC(O)OR5b, or —OSO2R5b;* *R5b is a straight chain or branched C1-C6 alkyl or a substituted or unsubstituted aryl;* *R9b is selected from a protecting group, a straight chain or branched C1-C6 alkyl, or a substituted or unsubstituted aryl;* ***R11b is hydrogen****;* ***R12b is a protecting group****; and* ***R6b, R7b, and R8b are each independently hydrogen or a straight chain or branched C1-C6 alkyl****;* *or a pharmaceutically acceptable acid-addition salt thereof;* *with the proviso that when R1b is hydrogen, R2b is methyl, R6b, R7b, and R8b are all hydrogen, and R12b is tert-butyloxycarbonyl (BOC) or methoxycarbonyl, then R3b is not hydrogen or methoxy; and* *with the proviso that when R1b and R2b are methyl, R6b, R7b, and R8b are all hydrogen, and R12b is ethoxycarbonyl, then R3b and R4b are not both methyl* 2. Int'l Pat. App. Pub. No. WO/2003/035,061 "Use of indole and indoline derivatives in the treatment of obesity or for the reduction of food intake" (Published May 1, 2003) From **Claim 1**: **Use of a compound having a structure in accordance with Formula** I, **II** or III:

	 **wherein n is 1** or 2... **R1 and R2 independently represent hydrogen, C1-C6 alkyl** or aryl, C1-C6 alkyl, or together represent the atoms necessary to complete a heterocycloalkyl group comprising the nitrogen atom to which R1 and R2 are attached; **R3 represents hydrogen**, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, C1-C6alkyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, C_ alkylcarbonyl, or C1-C6 alkoxycarbonyl; **R4 represents** arylsulphonyl, heteroarylsulphonyl, Cj-g alkylsulphonyl, di C1-C6 alkylaminosulphonyl, arylcarbonyl, C-C6 alkylcarbonyl, heteroarylcarbonyl or **C1-C6 alkoxycarbony**l; **each R5 independently represents hydrogen, hydroxy**, **C1-C6 alkoxy**, aryl C1-C6 alkoxy, nitrile or halogen;... **and A-B represents C=C** or CH-CH, in the manufacture of a medicament for the treatment and/or prevention of obesity or for the reduction of food intake.
62. The compound of claim 60, wherein at least one of R3b, R4b, R6b, R7b, and R8b is not hydrogen.	*From the application of interest 18/260,711, Claim 1:* *a tryptamine compound of formula (Ib):*  *wherein:* ***R1b is selected from hydrogen, straight chain or branched C1-C6 alkyl*** *or a straight chain or branched C2-C6 alkenyl;* ***R2b is selected from*** *a protecting group,* ***hydrogen, straight chain or branched C1-C6 alkyl*** *or a straight chain or branched C2-C6 alkenyl;* *R3b and R4b are independently chosen from* ***hydrogen, hydroxyl, —OR9b****, —OC(O)R5b, —OC(O)OR5b, or —OSO2R5b, provided that at least one of R3b or R4b is hydroxyl, —OR9b, —OC(O)R5b, —OC(O)OR5b, or —OSO2R5b;* *R5b is a straight chain or branched C1-C6 alkyl or a substituted or unsubstituted aryl;* *R9b is selected from a protecting group, a straight chain or branched C1-C6 alkyl, or a substituted or unsubstituted aryl;* ***R11b is hydrogen****;* ***R12b is a protecting group****; and*

	R6b, R7b, and R8b are each independently hydrogen or a straight chain or branched C1-C6 alkyl*;* *or a pharmaceutically acceptable acid-addition salt thereof;* *with the proviso that when R1b is hydrogen, R2b is methyl, R6b, R7b, and R8b are all hydrogen, and R12b is tert-butyloxycarbonyl (BOC) or methoxycarbonyl, then R3b is not hydrogen or methoxy; and* *with the proviso that when R1b and R2b are methyl, R6b, R7b, and R8b are all hydrogen, and R12b is ethoxycarbonyl, then R3b and R4b are not both methyl* 2. Int'l Pat. App. Pub. No. WO/2003/035,061 "Use of indole and indoline derivatives in the treatment of obesity or for the reduction of food intake" (Published May 1, 2003) From **Claim 1**: **Use of a compound having a structure in accordance with Formula** I, **II** or III:  **wherein n is 1** or 2... **R1 and R2 independently represent hydrogen, C1-C6 alkyl** or aryl, C1-C6 alkyl, or together represent the atoms necessary to complete a heterocycloalkyl group comprising the nitrogen atom to which R1 and R2 are attached; **R3 represents hydrogen**, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, C1-C6alkyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, C_ alkylcarbonyl, or C1-C6 alkoxycarbonyl; **R4 represents** arylsulphonyl, heteroarylsulphonyl, Cj-g alkylsulphonyl, di C1-C6 alkylaminosulphonyl, arylcarbonyl, C-C6 alkylcarbonyl, heteroarylcarbonyl or **C1-C6 alkoxycarbony**l; **each R5 independently represents hydrogen, hydroxy**, **C1-C6 alkoxy**, aryl C1-C6 alkoxy, nitrile or halogen;... **and A-B represents C=C** or CH-CH, in the manufacture of a medicament for the treatment and/or prevention of obesity or for the reduction of food intake.
63. The compound of claim 60, wherein at least one of R3b or R4b is not methyl.	*From the application of interest 18/260,711, Claim 1:* *a tryptamine compound of formula (Ib):* 

	wherein: ***R1b is selected from hydrogen, straight chain or branched C1-C6 alkyl*** *or a straight chain or branched C2-C6 alkenyl;* ***R2b is selected from*** *a protecting group,* ***hydrogen, straight chain or branched C1-C6 alkyl*** *or a straight chain or branched C2-C6 alkenyl;* *R3b and R4b are independently chosen from* ***hydrogen, hydroxyl, —OR9b****, —OC(O)R5b, —OC(O)OR5b, or —OSO2R5b, provided that at least one of R3b or R4b is hydroxyl, —OR9b, —OC(O)R5b, —OC(O)OR5b, or —OSO2R5b;* *R5b is a straight chain or branched C1-C6 alkyl or a substituted or unsubstituted aryl;* *R9b is selected from a protecting group, a straight chain or branched C1-C6 alkyl, or a substituted or unsubstituted aryl;* ***R11b is hydrogen****;* ***R12b is a protecting group****; and* ***R6b, R7b, and R8b are each independently hydrogen or a straight chain or branched C1-C6 alkyl****;* *or a pharmaceutically acceptable acid-addition salt thereof;* *with the proviso that when R1b is hydrogen, R2b is methyl, R6b, R7b, and R8b are all hydrogen, and R12b is tert-butyloxycarbonyl (BOC) or methoxycarbonyl, then R3b is not hydrogen or methoxy; and* *with the proviso that when R1b and R2b are methyl, R6b, R7b, and R8b are all hydrogen, and R12b is ethoxycarbonyl, then R3b and R4b are not both methyl* 2. Int'l Pat. App. Pub. No. WO/2003/035,061 "Use of indole and indoline derivatives in the treatment of obesity or for the reduction of food intake" (Published May 1, 2003) From **Claim 1**: **Use of a compound having a structure in accordance with Formula** I, **II** or III:  **wherein n is 1** or 2... **R1 and R2 independently represent hydrogen, C1-C6 alkyl** or aryl, C1-C6 alkyl, or together represent the atoms necessary to complete a heterocycloalkyl group comprising the nitrogen atom to which R1 and R2 are attached; **R3 represents hydrogen**, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, C1-C6alkyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, C_ alkylcarbonyl, or C1-C6 alkoxycarbonyl; **R4 represents** arylsulphonyl, heteroarylsulphonyl, Cj-g alkylsulphonyl, di C1-C6 alkylaminosulphonyl,

	arylcarbonyl, C-C6 alkylcarbonyl, heteroarylcarbonyl or **C1-C6 alkoxycarbony**l; **each R5 independently represents hydrogen, hydroxy**, **C1-C6 alkoxy**, aryl C1-C6 alkoxy, nitrile or halogen;... **and A-B represents C=C** or CH-CH, in the manufacture of a medicament for the treatment and/or prevention of obesity or for the reduction of food intake.
64. The compound of claim 60, wherein: R1b is methyl; R2b is selected from hydrogen, methyl, and a protecting group; R3b is selected from hydroxyl, —OR9b, —OC(O)R5b, —OC(O)OR5b, or —OSO2R5b; and R4b, R6b, R7b, and R8b are all hydrogen; with the proviso that R3b is not hydroxyl when R2b is methyl and R12b is a tert-butyloxycarbonyl (BOC) group.	*From the application of interest 18/260,711, Claim 1:* *a tryptamine compound of formula (Ib):*  *wherein:* ***R1b is selected from hydrogen, straight chain or branched C1-C6 alkyl*** *or a straight chain or branched C2-C6 alkenyl;* ***R2b is selected from*** *a protecting group,* ***hydrogen, straight chain or branched C1-C6 alkyl*** *or a straight chain or branched C2-C6 alkenyl;* *R3b and R4b are independently chosen from* ***hydrogen, hydroxyl, —OR9b****, —OC(O)R5b, —OC(O)OR5b, or —OSO2R5b, provided that at least one of R3b or R4b is hydroxyl, —OR9b, —OC(O)R5b, —OC(O)OR5b, or —OSO2R5b;* *R5b is a straight chain or branched C1-C6 alkyl or a substituted or unsubstituted aryl;* *R9b is selected from a protecting group, a straight chain or branched C1-C6 alkyl, or a substituted or unsubstituted aryl;* ***R11b is hydrogen****;* ***R12b is a protecting group****; and* ***R6b, R7b, and R8b are each independently hydrogen or a straight chain or branched C1-C6 alkyl****;* *or a pharmaceutically acceptable acid-addition salt thereof;* *with the proviso that when R1b is hydrogen, R2b is methyl, R6b, R7b, and R8b are all hydrogen, and R12b is tert-butyloxycarbonyl (BOC) or methoxycarbonyl, then R3b is not hydrogen or methoxy; and* *with the proviso that when R1b and R2b are methyl, R6b, R7b, and R8b are all hydrogen, and R12b is ethoxycarbonyl, then R3b and R4b are not both methyl* 2. Int'l Pat. App. Pub. No. WO/2003/035,061 "Use of indole and indoline derivatives in the treatment of obesity or for the reduction of food intake" (Published May 1, 2003) From **Claim 1**: **Use of a compound having a structure in accordance with Formula** I, **II** or III:

	 **wherein n is 1** or 2... **R1 and R2 independently represent hydrogen, C1-C6 alkyl** or aryl, C1-C6 alkyl, or together represent the atoms necessary to complete a heterocycloalkyl group comprising the nitrogen atom to which R1 and R2 are attached; **R3 represents hydrogen**, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, C1-C6alkyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, C_ alkylcarbonyl, or C1-C6 alkoxycarbonyl; **R4 represents** arylsulphonyl, heteroarylsulphonyl, Cj-g alkylsulphonyl, di C1-C6 alkylaminosulphonyl, arylcarbonyl, C-C6 alkylcarbonyl, heteroarylcarbonyl or **C1-C6 alkoxycarbony**l; **each R5 independently represents hydrogen, hydroxy**, **C1-C6 alkoxy**, aryl C1-C6 alkoxy, nitrile or halogen;... **and A-B represents C=C** or CH-CH, in the manufacture of a medicament for the treatment and/or prevention of obesity or for the reduction of food intake.
65. The compound of claim 55, wherein the tryptamine compound is a compound of formula (I).	*From the application of interest 18/260,711, Claim 1:* *a tryptamine compound of formula (I):*  *wherein* ***R1 is selected from hydrogen, straight chain or branched C1-C6 alkyl** or a straight chain or branched C2-C6 alkenyl;* ***R2 is selected from** a protecting group, **hydrogen, straight chain or branched C1-C6 alkyl** or a straight chain or branched C2-C6 alkenyl;* ***R3 and R4 are independently chosen from hydrogen, hydroxyl, —OR9,** —OC(O)R5, —OC(O)OR5, or —OSO2R5;* *R5 is a straight chain or branched C1-C6 alkyl or a substituted or unsubstituted aryl;* ***R9 is selected from** a protecting group, **a straight chain or branched C1-C6 alkyl, or a substituted or unsubstituted aryl**;* ***R6, R7, R8, and R11 are each independently hydrogen** or a straight chain or branched C1-C6 alkyl; and* ***R12 is selected from a protecting grou**p, hydrogen, a straight chain or branched C1-C6 alkyl or a straight chain or branched C2-C6 alkenyl, wherein at least one of R2 or R12 is a protecting group;* *or a pharmaceutically acceptable acid-addition salt thereof;*

	wherein the purity of the tryptamine compound of formula (I) is greater than 98%. 2. Int'l Pat. App. Pub. No. WO/2003/035,061 "Use of indole and indoline derivatives in the treatment of obesity or for the reduction of food intake" (Published May 1, 2003) From **Claim 1**: **Use of a compound having a structure in accordance with Formula** I, **II** or III:  **wherein n is 1** or 2... **R1 and R2 independently represent hydrogen, C1-C6 alkyl** or aryl, C1-C6 alkyl, or together represent the atoms necessary to complete a heterocycloalkyl group comprising the nitrogen atom to which R1 and R2 are attached; **R3 represents hydrogen**, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, C1-C6alkyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, C_ alkylcarbonyl, or C1-C6 alkoxycarbonyl; **R4 represents arylsulphonyl**, heteroarylsulphonyl, Cj-g alkylsulphonyl, di C1-C6 alkylaminosulphonyl, arylcarbonyl, C-C6 alkylcarbonyl, heteroarylcarbonyl or C1-C6 alkoxycarbonyl; **each R5 independently represents hydrogen, hydroxy**, **C1-C6 alkoxy**, aryl C1-C6 alkoxy, nitrile or halogen;... **and A-B represents C=C** or CH-CH, in the manufacture of a medicament for the treatment and/or prevention of obesity or for the reduction of food intake. From **Description**: **Compound: The test compound, N,N-Dimethyl 2-[1 -(benzenesulphonyl)-5-methoxy- 1 H-indol-3-yl]ethylamine**. **The purity of the test compounds is of analytical grade.**
66. N—BOC-Norpsilocin or a pharmaceutically-acceptable addition salts thereof.	1. U.S. Pat. App. Pub. No. US/2016/0353739 "Use of aryl carbamates in agriculture and other plant-related areas" (Published December 8, 2016) From **Claim 1:** A method of preventing, removing or inhibiting microbial biofilm formation or microbial infection in a plant or plant part thereof, comprising applying to said plant or plant part a treatment effective amount of a compound of **Formula (I)**:

	 wherein: **R1 is an** aryl, an amine-substituted aryl, or a **heteroaryl having at least one nitrogen atom; n=0 to 10**, saturated or unsaturated; **each occurrence of Rx and Ry** is present or absent (depending upon chain saturation), and **is each independently H** or alkyl; **R2 is selected from the group consisting of**: H, **alkyl**, alkenyl and alkynyl; and **R3 is alkyl**, substituted cycloalkyl or unsubstituted cycloalkyl, or an agriculturally acceptable salt thereof. From **Description**: **"Heteroaryl" means a cyclic, aromatic hydrocarbon in which one or more carbon atoms have been replaced with heteroatoms (e.g., N, O or S). If the heteroaryl group contains more than one heteroatom, the heteroatoms may be the same or different. Examples of heteroaryl groups include** pyridyl, pyrimidinyl, imidazolyl, thienyl, furyl, pyrazinyl, pyrrolyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, **indolyl**, isoindolyl, indolizinyl, triazolyl, pyridazinyl, indazolyl, purinyl, quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, isothiazolyl, and benzo[b]thienyl. Preferred heteroaryl groups are five and six membered rings and contain from one to three heteroatoms independently selected from the group consisting of: O, N, and S. **The heteroaryl group, including each heteroatom, can be unsubstituted or substituted with from 1 to 4 suitable substituents, as chemically feasible.**
67. N—BOC-4-Acetoxy-Norpsilocin or a pharmaceutically-acceptable addition salt thereof.	1. U.S. Pat. App. Pub. No. US/2016/0353739 “Use of aryl carbamates in agriculture and other plant-related areas” (Published December 8, 2016) From **Claim 1:** A method of preventing, removing or inhibiting microbial biofilm formation or microbial infection in a plant or plant part thereof, comprising applying to said plant or plant part a treatment effective amount of a compound of **Formula (I)**:  wherein:

	R1 is an aryl, an amine-substituted aryl, or a **heteroaryl having at least one nitrogen atom; n=0 to 10**, saturated or unsaturated; **each occurrence of Rx and Ry** is present or absent (depending upon chain saturation), and **is each independently H** or alkyl; **R2 is selected from the group consisting of**: H, **alkyl**, alkenyl and alkynyl; and **R3 is alkyl**, substituted cycloalkyl or unsubstituted cycloalkyl, or an agriculturally acceptable salt thereof. From **Description**: **"Heteroaryl" means a cyclic, aromatic hydrocarbon in which one or more carbon atoms have been replaced with heteroatoms (e.g., N, O or S). If the heteroaryl group contains more than one heteroatom, the heteroatoms may be the same or different. Examples of heteroaryl groups include** pyridyl, pyrimidinyl, imidazolyl, thienyl, furyl, pyrazinyl, pyrrolyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, **indolyl**, isoindolyl, indolizinyl, triazolyl, pyridazinyl, indazolyl, purinyl, quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, isothiazolyl, and benzo[b]thienyl. Preferred heteroaryl groups are five and six membered rings and contain from one to three heteroatoms independently selected from the group consisting of: O, N, and S. **The heteroaryl group, including each heteroatom, can be unsubstituted or substituted with from 1 to 4 suitable substituents, as chemically feasible.**
68. A composition comprising a compound of claim 55 or a pharmaceutically-acceptable acid addition salt thereof, and an excipient.	*From the application of interest 18/260,711, Claim 1:* *a tryptamine compound of formula (Ib):*  *wherein:* ***R1b is selected from hydrogen, straight chain or branched C1-C6 alkyl** or a straight chain or branched C2-C6 alkenyl; **R2b is selected from** a protecting group, **hydrogen, straight chain or branched C1-C6 alkyl** or a straight chain or branched C2-C6 alkenyl;* *R3b and R4b are independently chosen from **hydrogen, hydroxyl, —OR9b**, —OC(O)R5b, —OC(O)OR5b, or —OSO2R5b, provided that at least one of R3b or R4b is hydroxyl, —OR9b, —OC(O)R5b, —OC(O)OR5b, or —OSO2R5b;* *R5b is a straight chain or branched C1-C6 alkyl or a substituted or unsubstituted aryl;* *R9b is selected from a protecting group, a straight chain or branched C1-C6 alkyl, or a substituted or unsubstituted aryl;* ***R11b is hydrogen**;* ***R12b is a protecting group**; and*

	R6b, R7b, and R8b are each independently hydrogen or a straight chain or branched C1-C6 alkyl*;* *or a pharmaceutically acceptable acid-addition salt thereof;* *with the proviso that when R1b is hydrogen, R2b is methyl, R6b, R7b, and R8b are all hydrogen, and R12b is tert-butyloxycarbonyl (BOC) or methoxycarbonyl, then R3b is not hydrogen or methoxy; and* *with the proviso that when R1b and R2b are methyl, R6b, R7b, and R8b are all hydrogen, and R12b is ethoxycarbonyl, then R3b and R4b are not both methyl* 2. Int'l Pat. App. Pub. No. WO/2003/035,061 "Use of indole and indoline derivatives in the treatment of obesity or for the reduction of food intake" (Published May 1, 2003) From **Claim 1**: **Use of a compound having a structure in accordance with Formula** I, **II** or III:  **wherein n is 1** or 2... **R1 and R2 independently represent hydrogen, C1-C6 alkyl** or aryl, C1-C6 alkyl, or together represent the atoms necessary to complete a heterocycloalkyl group comprising the nitrogen atom to which R1 and R2 are attached; **R3 represents hydrogen**, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, C1-C6alkyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, C_ alkylcarbonyl, or C1-C6 alkoxycarbonyl; **R4 represents** arylsulphonyl, heteroarylsulphonyl, Cj-g alkylsulphonyl, di C1-C6 alkylaminosulphonyl, arylcarbonyl, C-C6 alkylcarbonyl, heteroarylcarbonyl or **C1-C6 alkoxycarbony**l; **each R5 independently represents hydrogen, hydroxy**, **C1-C6 alkoxy**, aryl C1-C6 alkoxy, nitrile or halogen;... **and A-B represents C=C** or CH-CH, in the manufacture of a medicament for the treatment and/or prevention of obesity or for the reduction of food intake. From **Description**: **Such pharmaceutical compositions according to the invention comprise an effective amount of one, or optionally more, compound(s) discussed above in association with compatible pharmaceutically acceptable carrier materials, or diluents, as are well known in the art. The carriers may be any inert material, organic or inorganic, suitable for oral, enteral, rectal, percutaneous, subcutaneous or parenteral administration...**
69. A composition comprising as a first	3. U.S. Pat. App. Pub. No. US/2018/0021326 "Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom

active component: a compound of claim 55; and as a second active component selected from at least one of (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) a purified cannabinoid, (d) a monoamine oxidase inhibitor, (e) a purified terpene, (f) an adrenergic drug, (g) a dopaminergic drug, (h) a purified erinacine, or (i) a purified hericenone; and a pharmaceutically acceptable excipient.	extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin" (Published 25 January 2018) From **Description**: **Compounds naturally produced by the mycelium of psilocybian mushrooms and their mycelium includes baeocystin, norbaeocystin, N,N-dimethyltryptamine, 5-hydroxytryptamine (serotonin), 5-hydroxytryptophan, psilocybin and psilocin. These compounds, their precursors and immediate derivatives are candidates for neurogenesis. Synthetic or natural prodrugs,** congeners and analogs **of psilocybin, psilocin, baeocystin and norbaeocystin may offer similar benefits.** From **Claim 11: The method of claim 1, wherein the composition additionally comprises one or more of** (Bacopa monnieri), Gotu kola (Centella asiatica), Gingko (Gingko biloba), Ginger (Zingiber officinale), Holy Basil (Ocimum sanctum), Hu Zhang (Polygonum cuspidatum), Oregano (Origanum vulgare, Origanum onites), Rosemary (Rosmarinus officinalis, Rosmarinus eriocalyx, Rosmarinus species), Turmeric (Curcuma longa), Green Tea (Camellia sinensis), lavender (Lavandula spica and Lavandula species), skullcap (Scutellaria lateriflora), oat straw (Avena sativa and Avena byzantine), Diviner's Sage (Salvia divinorum), ayahuasca (Banisteriopsis caapi and Psychotria species), Tabernanthe iboga, Voacanga africana, Tabernaemontana undulate, peyote (Lophophora williamsii), morning glory (Ipomoea tricolor, Argyreia nervosa), **Cannabis sativa, Cannabis indica or Cannabis ruderalis**, or combinations thereof.
70. A method of preventing or treating a psychological disorder comprising: identifying a subject in need of treatment or prevention; and administering to a subject in need thereof a therapeutically effective amount of a compound of claim 55.	*From the application of interest 18/260,711, Claim 1:* *a tryptamine compound of formula (Ib):*  *wherein:* ***R1b is selected from hydrogen, straight chain or branched C1-C6 alkyl** or a straight chain or branched C2-C6 alkenyl;* ***R2b is selected from** a protecting group, **hydrogen, straight chain or branched C1-C6 alkyl** or a straight chain or branched C2-C6 alkenyl;* ***R3b and R4b are independently chosen from hydrogen, hydroxyl, —OR9b**, —OC(O)R5b, —OC(O)OR5b, or —OSO2R5b, provided that at least one of R3b or R4b is hydroxyl, —OR9b, —OC(O)R5b, —OC(O)OR5b, or —OSO2R5b;* *R5b is a straight chain or branched C1-C6 alkyl or a substituted or unsubstituted aryl;* *R9b is selected from a protecting group, a straight chain or branched C1-C6 alkyl, or a substituted or unsubstituted aryl;*

	***R11b is hydrogen**;* ***R12b is a protecting group**; and* ***R6b, R7b, and R8b are each independently hydrogen or a straight chain or branched C1-C6 alkyl**;* *or a pharmaceutically acceptable acid-addition salt thereof;* *with the proviso that when R1b is hydrogen, R2b is methyl, R6b, R7b, and R8b are all hydrogen, and R12b is tert-butyloxycarbonyl (BOC) or methoxycarbonyl, then R3b is not hydrogen or methoxy; and* *with the proviso that when R1b and R2b are methyl, R6b, R7b, and R8b are all hydrogen, and R12b is ethoxycarbonyl, then R3b and R4b are not both methyl* 2. Int'l Pat. App. Pub. No. WO/2003/035,061 "Use of indole and indoline derivatives in the treatment of obesity or for the reduction of food intake" (Published May 1, 2003) From **Claim 1**: **Use of a compound having a structure in accordance with Formula** I, **II** or III:  **wherein n is 1** or 2... **R1 and R2 independently represent hydrogen, C1-C6 alkyl** or aryl, C1-C6 alkyl, or together represent the atoms necessary to complete a heterocycloalkyl group comprising the nitrogen atom to which R1 and R2 are attached; **R3 represents hydrogen**, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, C1-C6alkyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, C_ alkylcarbonyl, or C1-C6 alkoxycarbonyl; **R4 represents arylsulphonyl**, heteroarylsulphonyl, Cj-g alkylsulphonyl, di C1-C6 alkylaminosulphonyl, arylcarbonyl, C-C6 alkylcarbonyl, heteroarylcarbonyl or C1-C6 alkoxycarbonyl; **each R5 independently represents hydrogen, hydroxy**, **C1-C6 alkoxy**, aryl C1-C6 alkoxy, nitrile or halogen;... **and A-B represents C=C** or CH-CH, **in the manufacture of a medicament for the treatment and/or prevention of obesity or for the reduction of food intake.**
71. A method of generating a	

monoalkyltryptamine compound in situ in a patient, the method comprising administering to a patient a compound of claim 55.	
72. A method of preventing or treating inflammation and/or pain comprising: identifying a subject in need of treatment or prevention; and administering to a subject in need thereof a therapeutically effective amount of a compound of claim 55.	3. U.S. Pat. App. Pub. No. US/2018/0021326 "Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin" (Published 25 January 2018) From **Description**: **Compounds naturally produced by the mycelium of psilocybian mushrooms and their mycelium includes baeocystin, norbaeocystin, N,N-dimethyltryptamine, 5-hydroxytryptamine (serotonin), 5-hydroxytryptophan, psilocybin and psilocin. These compounds, their precursors and immediate derivatives are candidates for neurogenesis. Synthetic or natural prodrugs,** congeners and analogs **of psilocybin, psilocin, baeocystin and norbaeocystin may offer similar benefits.** From **Claim 11: The method of claim 1, wherein the composition additionally comprises one or more of** (Bacopa monnieri), Gotu kola (Centella asiatica), Gingko (Gingko biloba), Ginger (Zingiber officinale), Holy Basil (Ocimum sanctum), Hu Zhang (Polygonum cuspidatum), Oregano (Origanum vulgare, Origanum onites), Rosemary (Rosmarinus officinalis, Rosmarinus eriocalyx, Rosmarinus species), Turmeric (Curcuma longa), Green Tea (Camellia sinensis), lavender (Lavandula spica and Lavandula species), skullcap (Scutellaria lateriflora), oat straw (Avena sativa and Avena byzantine), Diviner's Sage (Salvia divinorum), ayahuasca (Banisteriopsis caapi and Psychotria species), Tabernanthe iboga, Voacanga africana, Tabernaemontana undulate, peyote (Lophophora williamsii), morning glory (Ipomoea tricolor, Argyreia nervosa), **Cannabis sativa, Cannabis indica or Cannabis ruderalis**, or combinations thereof. From **Description**: **Plant extracts with known neuroregenerative properties include, but are not limited to**: Bacopa species (Bacopa monnieri), Gotu kola (Centella asiatica), and Gingko (Gingko biloba). Additional plants with anti-inflammatory properties include but are not limited to: Ginger (Zingiber officinale), Holy Basil (Ocimum sanctum), Hu Zhang (Polygonum cuspidatum), Oregano (Origanum vulgare, Origanum onites), Rosemary (Rosmarinus officinalis, Rosmarinus eriocalyx, species in the genus Rosmarinus), Turmeric (Curcuma longa), Green Tea (Camellia sinensis), lavender (Lavandula spica and related species in the genus Lavandula), skullcap (Scutellaria lateriflora) and oat straw (Avena sativa, Avena byzantina). Moreover, Salvia divinorum, aka Diviner's Sage, ayahuasca, a concoction made from Banisteriopsis caapi and Psychotria species, and plants containing ibogaine (Tabernanthe iboga, Voacanga africana and Tabernaemontana undulate), peyote (Lophophora williamsii),

	the seeds of morning glory (Ipomoea tricolor and related species) and Hawaiian baby woodrose (Argyreia nervosa), and **Cannabis (Cannabis sativa, C. indica and C. ruderalis)...**

UNITED STATES PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
18/260,711	**08/29/2024 12:29:58 PM Z ET**	

Title of Invention

Application Information

APPLICATION TYPE		PATENT #	
CONFIRMATION #		FILED BY	Jeremy Rolquin
PATENT CENTER #	66974712	FILING DATE	07/07/2023
CUSTOMER #	–	FIRST NAMED INVENTOR	
INTL. APPLICATION #	-	INTL. FILING DATE	-
CORRESPONDENCE ADDRESS	-	AUTHORIZED BY	-

Documents

TOTAL DOCUMENTS: 7

DOCUMENT		PAGES	DESCRIPTION	SIZE (KB)
third-party-preissuance-submission.pdf		2	Third-Party Submission Under 37 CFR 1.290	45 KB
Concise-description-generated.pdf		2	Concise Description of Relevance	25 KB
Third-party-notification-request.pdf		1	Request for Notification of Non-compliant Third-Party Submission	13 KB
US20240083848 3PS Embedded.pdf		27	-	364 KB
US20240083848 3PS Embedded-3P.RELEVANCE.pdf	(1-27)	27	Concise Description of Relevance	365 KB
US20240083848 3PS	(1-27)	27	Concise Description of	365 KB

Embedded-3P.RELEVANCE.pdf			Relevance	
US20240083848 3PS Embedded-3P.RELEVANCE.pdf	(1-27)	27	Concise Description of Relevance	365 KB
2_WO2003035061A1.pdf		32	-	939 KB
2_WO2003035061A1-FOR.pdf	(1-32)	32	Foreign Reference	935 KB

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)
third-party-preissuance-submission.pdf	850E587783D87184D3EFD9378780B3CE500EAA48341D773DBE954BA09F102A530CF443991909B1DB9BC52C751BE695567C1CE7A05F6D28905C91883D5B7F46FB
Concise-description-generated.pdf	300A038F15EF2D5EC0581B9A1BA02434F25BCAC8C7544868B6F995D0BCCF46F2455F794D966D0FC7C2F9BA7EFE355BC404B5F564977029C8AB2D1E7B2D461BE9
Third-party-notification-request.pdf	0FCD1505B25D86CEA0134391EB10DE3126DCE1E9A5EA0840F30FAD19D29916BEFE680B4A9574F9A7AAD4D4288A811C7F81519EC757FEEFE1F6BAEF5D0560D091
US20240083848 3PS Embedded.pdf	E5B212CA542DF4F8FA3DFAA507611035952C26E5EE0AFA202673DBB81774F2FAE4813A9CDCAEC5ABF212EBE1E2686E05A924111F898A55A429C2666F72D48623
US20240083848 3PS Embedded-3P.RELEVANCE.pdf	43A8B3F6819A22655BAC4B96461A1AF0BE0EF196857FECC1F0C0B84515C0EC67B0371E439D340AAF5A5CD7099315DE29DC2A183FC1AD554D259FB60F7672CA61
US20240083848 3PS Embedded-3P.RELEVANCE.pdf	1F1E831730A0C9CB9C5002D8FE07CDC9C5D50AD1A99685B0DD3932DA6A4238E24E785CAB3C2DF78677EA61392EAE1966EB7CC002B58BE5E3B44B562CBE4AF993
US20240083848 3PS Embedded-3P.RELEVANCE.pdf	8D5E5954F55CD269402E7CD719EB7798F9D80501DB48808202620AF87A0015051DB55112FFB26F42D3474AA4BC09A8DB49D4224FB4D3C9609C5B51F3BAD22268
2_WO2003035061A1.pdf	CFBC70323DE454DBAF31C16F24096D732BE3674968E54FF495E01FBC2E3D7EB937511EEDB5106E0EB201BB5672E9D551003C921A1BA2C3DD3C2BA85CB414AF7F
2_WO2003035061A1-FOR.pdf	0AE17E6B218E9FF4D36F290186FA4C8D1E05BD7662B0EAA1C4EF6E364126FCA642A5B6772A1EB83311395F79988DD33D0A560B37D78B5DB0BEB560F37E9F440D

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.